Clinical Trial

DCN Dx to Highlight Lateral Flow Development Services and miniDxR at MEDICA 2024

Explore DCN Dx's contract IVD services and customizable lateral flow reader at Booth Hall 3 / D25-2 CARLSBAD, Calif., Oct.…

1 year ago

Google Cloud Launches General Availability of Vertex AI Search for Healthcare and Healthcare Data Engine

Google Cloud's solutions help healthcare organizations improve medical systems and provide better care SUNNYVALE, Calif., Oct. 17, 2024 /PRNewswire/ --…

1 year ago

IgniteData Secures Enterprise Agreement for Archer Platform, Streamlining EHR-to-EDC Data Transfer

WILMINGTON, Del., Oct. 17, 2024 /PRNewswire/ -- IgniteData, a company focused on healthcare technology solutions, announces a new collaboration with…

1 year ago

Biodexa’s MX-110 Continues to Show Promise in Recurrent Glioblastoma (rGBM), the Deadliest Brain Cancer

In a small but important Phase 1 study, MTX110 is outperforming historic norms of progression free and overall survivalCARDIFF, UK…

1 year ago

Biodexa’s MX-110 Continues to Show Promise in Recurrent Glioblastoma (rGBM), the Deadliest Brain Cancer

In a small but important Phase 1 study, MTX110 is outperforming historic norms of progression free and overall survivalCARDIFF, UK…

1 year ago

Intercept Provides Regulatory Update Regarding sNDA for OCALIVA

MORRISTOWN, N.J., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc., a wholly owned subsidiary of Alfasigma S.p.A., today announced…

1 year ago

Sonnet BioTherapeutics Inc. Regains Compliance with Nasdaq

PRINCETON, NJ, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the “Company” or “Sonnet”) (NASDAQ: SONN), a clinical-stage…

1 year ago

New Study Shows Nexalin’s Deep Intracranial Frequency Stimulation (DIFS) Significantly Improves Memory and Cognitive Function in Alzheimer’s Patients

Groundbreaking Trial Reveals DIFS Increases Neural Activity and Blood Flow in the Hippocampus, Offering Hope for Alzheimer’s TreatmentHOUSTON, TX, Oct.…

1 year ago

Tarsus Launches “Your Mitey Problem,” the First Direct-to-Consumer TV Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25%

Campaign showcases root cause of Demodex blepharitis through creative representation of mischief-causing mites on patients’ eyelids Demodex blepharitis is a…

1 year ago

Inozyme Pharma Announces Presentation of Interim Data from Phase 1 SEAPORT 1 Trial at the Upcoming American Society of Nephrology (ASN) Kidney Week 2024

BOSTON, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing…

1 year ago